Why Did Axon Enterprise (AXON) Stock Move Up +17.56% Today?
Key Takeaways
- AXON surged approximately +17.56% on February 25, 2026, closing at $520.18 versus the prior session's close of $442.51
- The primary catalyst was a blowout Q4 2025 earnings report, with adjusted EPS of $2.15 crushing the consensus estimate of approximately $1.67
- Q4 revenue of $797 million rose 39% year-over-year and came in well above Wall Street's ~$754 million forecast
- Management issued strong 2026 guidance of 27%–30% revenue growth and set ambitious 2028 targets of $6 billion in annual revenue
- AI-driven demand for software and services, accelerating bookings, and a $14.4 billion future contracted backlog reinforced long-term visibility
- Analysts reiterated and adjusted price targets broadly upward after the print, with consensus remaining a strong "Buy"
Opening Summary
Axon Enterprise, Inc. (AXON) is a Scottsdale, Arizona-based public safety technology company best known for its TASER devices, body-worn cameras, drone systems, and a rapidly expanding suite of AI-powered software and cloud services for law enforcement and government agencies. Shares surged approximately +17.56% in the February 25, 2026 session, closing at $520.18 compared to the prior close of $442.51, as the company delivered fourth-quarter 2025 results that significantly exceeded analyst expectations on both the top and bottom lines. Volume spiked to over 4.4 million shares, well above the stock's typical daily average, as investors responded enthusiastically to the earnings beat and bullish guidance.
Earnings Beat Drives the Rally
The headline driver was an unambiguous earnings beat. AXON reported Q4 2025 adjusted EPS of $2.15, topping the Zacks consensus estimate of $1.67 — a beat of nearly 29%. Revenue came in at $797 million, representing 39% growth year-over-year and exceeding the analyst consensus of approximately $754 million. Software & Services revenue — Axon's highest-margin segment — grew 40% year-over-year to $343 million, a figure that underscored the company's ongoing transition from a hardware-centric business to a recurring-revenue, software-first platform.
Adjusted EBITDA for the quarter reached $206 million, a 46% increase year-over-year, while full-year 2025 revenue hit $2.8 billion, up 33% from the prior year. Future contracted bookings totaled $14.4 billion, up 43% year-over-year, providing unusually high visibility into future revenue streams.
AI and Software Momentum as a Structural Catalyst
Beyond the headline numbers, CEO Rick Smith's commentary on artificial intelligence resonated strongly with investors. Smith described the current moment as "unlike anything" he had seen since founding the company in 1993, emphasizing that aggressive deployment of AI within Axon's product ecosystem creates defensible competitive advantages. CFO Brittany Bagley reinforced this narrative, noting that the software segment — boosted by AI-enabled tools like Axon's voice-activated body camera companion — is expected to surpass hardware growth in the near term.
Axon's AI-powered draft tools, real-time translation features, and automated evidence management services are driving higher software attach rates across its existing customer base and opening doors with new agency clients. This software pivot, increasingly tied to AI capabilities, is what analysts say supports Axon's premium valuation relative to traditional defense and public safety hardware vendors.
2026 Guidance and 2028 Targets Surprise to the Upside
Management's forward guidance added substantial fuel to the rally. AXON set full-year 2026 revenue growth guidance of 27% to 30%, ahead of the prior Street consensus of approximately 25.8% growth. The company also targeted a 25.5% Adjusted EBITDA margin for 2026.
Perhaps more impactful was the introduction of a 2028 target model calling for approximately $6 billion in annual revenue and a 28% Adjusted EBITDA margin — both figures that materially exceeded analyst consensus expectations at the time. These long-range targets were underpinned by record 2025 bookings of $7.4 billion and the $14.4 billion future contracted backlog, which together give investors a high degree of confidence in multi-year revenue visibility.
Analyst Reactions and Price Target Adjustments
Multiple Wall Street firms weighed in on the results. Barclays maintained an "Overweight" rating and adjusted its price target to $682, still implying significant upside from the pre-earnings close. Craig-Hallum maintained a Buy rating with a $820 target, citing strong results and above-consensus 2026 guidance. Raymond James reiterated an Outperform rating at $800, praising Axon's momentum and its 2028 targets that exceeded consensus. Goldman Sachs maintained a Buy rating with an $800 price target. The broad analyst consensus remained "Moderate Buy," with the consensus price target above $680.
Market Context and Trading Activity
The broader market on February 25 provided a somewhat mixed backdrop, but AXON's move was clearly earnings-driven and idiosyncratic rather than sector-wide. Volume of over 4.4 million shares represented a significant spike above average daily trading levels, consistent with a major catalyst-driven event. The stock opened sharply higher in pre-market trading — above $513 by early morning — reflecting immediate institutional buying following the after-hours earnings release. Shares traded between an intraday low of $498.43 and a high of $551.97 during the session before settling at $520.18, suggesting some intraday profit-taking after the initial surge.
Trending AI Robots
For traders and investors looking to act on momentum like AXON's earnings-driven surge, Tickeron offers a curated selection of AI-powered trading bots through its Trending AI Robots page. Tickeron operates hundreds of AI trading bots covering thousands of tickers across multiple asset classes, but only the top-performing bots under current market conditions are featured in this section. Each bot varies by strategy, timeframe, risk profile, traded symbols, and performance metrics — giving users flexibility to find a bot that matches their trading style. Whether you prefer short-term momentum plays, swing trading, or longer-horizon strategies, the Trending AI Robots section highlights which bots are delivering results right now. Explore the page to discover which AI-driven strategies are gaining traction in today's market environment.
What Comes Next for AXON
Looking ahead, AXON's next major catalyst will be its Q1 2026 earnings report, where investors will assess whether the strong bookings and software momentum translate into continued top-line outperformance. Key items to watch include the pace of software attach rate growth, updates on AI product rollouts, and any developments in large-scale government or international contract wins. Analysts will also be monitoring whether the company's 2026 EBITDA margin guidance of 25.5% holds as it continues to invest heavily in R&D and headcount expansion.
Risks include elevated stock-based compensation — projected at $590–620 million for 2026 — which will continue to weigh on GAAP profitability even as non-GAAP metrics remain strong. Broader macro risks such as federal budget pressures, potential cuts to law enforcement technology spending, and tariff-related cost pressures on hardware remain worth monitoring. The stock's rich valuation, trading at a significant premium to the broader market, also means that any execution misstep or guidance reduction could result in an outsized negative reaction.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for AXON turns positive, indicating new upward trend
AXON saw its Momentum Indicator move above the 0 level on June 26, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 82 similar instances where the indicator turned positive. In of the 82 cases, the stock moved higher in the following days. The odds of a move higher are at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for AXON just turned positive on June 29, 2026. Looking at past instances where AXON's MACD turned positive, the stock continued to rise in of 41 cases over the following month. The odds of a continued upward trend are .
AXON moved above its 50-day moving average on June 23, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for AXON crossed bullishly above the 50-day moving average on June 01, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where AXON advanced for three days, in of 371 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 262 cases where AXON Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for AXON moved out of overbought territory on June 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 40 similar instances where the indicator moved out of overbought territory. In of the 40 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AXON declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
AXON broke above its upper Bollinger Band on May 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. AXON’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 72, placing this stock slightly better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.355) is normal, around the industry mean (10.983). P/E Ratio (165.335) is within average values for comparable stocks, (94.507). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.106). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (11.351) is also within normal values, averaging (37.421).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical-stage biopharmaceutical company
Industry AerospaceDefense
Advertisement